<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149697">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01934088</url>
  </required_header>
  <id_info>
    <org_study_id>2013052044 v.1</org_study_id>
    <nct_id>NCT01934088</nct_id>
  </id_info>
  <brief_title>Satisfaction With Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl Sedation for Endoscopy</brief_title>
  <official_title>Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copenhagen University Hospital at Herlev</source>
  <oversight_info>
    <authority>Denmark: GCP-Unit at Copenhagen Universityhospital</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sedation for endoscopy is a service more than a necessity. Therefore it should be patient
      driven. Patients with inflammatory bowel disease (IBD) undergoes life long endoscopic
      control. Therefore, satisfaction with the procedure experience is paramount for patients
      with IBD. Investigators wish to study the feasibility and the effect on patient experience
      of two drugs. Propofol administered by endoscopy nurses (NAPS) and conventional therapy with
      a combination of fentanyl and midazolam. Investigators hypothesize that patients sedated
      with propofol has a better procedure experience, that a well performed sedation equals a
      better experience and that NAPS is as feasible as fentanyl with midazolam sedation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>Participants will be interviewed when an Aldrete recovery score of 12 is achieved, an expected average of 2 hours after admission</time_frame>
    <safety_issue>No</safety_issue>
    <description>Satisfaction points in a post procedure questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-disposing factors for satisfaction with procedure and sedation</measure>
    <time_frame>At admission to the hospital at time 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>pre-operative questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation between quality of sedation and satisfaction</measure>
    <time_frame>At the end of procedure, an expected average of 1 hour after admission</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sedation efficacy is measured through use of a previously developed competency assessment tool. The quality of sedation score. The score is correlated with patient satisfaction</description>
  </other_outcome>
  <other_outcome>
    <measure>Feasibilty of method</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Timespand from entering the OR until discharge. Safety parameters during sedation. Number of adverse events, number of airway interventions, number of rescue treatments</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Endoscopy</condition>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol in refract doses. Induction: 10-60 mg supplemented with 10-30 mg following an age correlated algorithm. Maintenance with refract bolus of 10-20 mg every 1-2 minutes after assessed need and condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl and Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.025-0.05 mg of Fentanyl i.v. minimum 5 minutes before procedure as a single shot. Midazolam 1-2 mg i.v. for induction and 0.5-1 mg i.v. for maintenance after assessing needs and condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <arm_group_label>Fentanyl and Midazolam</arm_group_label>
    <other_name>Midazolam &quot;Hameln&quot; ATC-code: N05CD08</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <arm_group_label>Fentanyl and Midazolam</arm_group_label>
    <other_name>Fentanyl &quot;Hameln&quot; ATC-code: N01AH01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inflammatory Bowel Disease (IBD) or suspected IBD

          -  Planned Endoscopy

          -  Candidate for propofol sedation

          -  willingness to be randomized

          -  Ability to complete questionnaire

        Exclusion Criteria:

          -  Allergy to drugs

          -  American Society of Anesthesiologists Class III

          -  Body Mass Index &gt; 35

          -  Ventricular retention

          -  Acute condition

          -  Severe Chronic obstructive pulmonary disease

          -  Sleep apnea

          -  Potentially difficult airway or previous difficulty with anesthesia

          -  Pregnancy

          -  &lt;18 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeppe Thue Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenheden D, endoscopy, Herlev Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Vilmann, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Gastroenheden D, Endoscopy, Herlev Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeppe Thue Jensen, MD</last_name>
    <phone>004526136032</phone>
    <email>jeppe.thue.jensen.01@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Vilmann, Professor</last_name>
    <email>peter.vilmann@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endoscopy, Gastrounit, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <state>Region H</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jakob Hendel, MD</last_name>
      <email>Jakob.Hendel@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Jeppe Thue Jensen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Jensen JT, Vilmann P, Horsted T, Hornslet P, Bodtger U, Banning A, Hammering A. Nurse-administered propofol sedation for endoscopy: a risk analysis during an implementation phase. Endoscopy. 2011 Aug;43(8):716-22. doi: 10.1055/s-0030-1256515. Epub 2011 Aug 2.</citation>
    <PMID>21811940</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>August 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen University Hospital at Herlev</investigator_affiliation>
    <investigator_full_name>Jeppe Thue Jensen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Inflammatory Bowel disease</keyword>
  <keyword>IBD</keyword>
  <keyword>Sedation</keyword>
  <keyword>NAPS</keyword>
  <keyword>Propofol</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Satisfaction</keyword>
  <keyword>Feasibility</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
